Hydroxychloroquine reverses the prothrombotic state in a mouse model of antiphospholipid syndrome: Role of reduced inflammation and endothelial dysfunction

PLoS ONE

Volumn 14, Issue 3, 2019, Pages

  Miranda, Sébastien ^a,b,c   Billoir, Paul ^a,b   Damian, Louise ^a,b,c   Thiebaut, Pierre Alain ^a,b,c   Schapman, Damien ^c   Le Besnerais, Maelle ^a,b,c   Jouen, Fabienne ^c,d   Galas, Ludovic ^c   Levesque, Hervé ^a,b,c   Le Cam Duchez, Véronique ^a,b   Joannides, Robinson ^b,c   Richard, Vincent ^b,c   Benhamou, Ygal ^a,b,c  

^a ROUEN UNIVERSITY HOSPITAL   (France)

^b UNIVERSITÉ DE ROUEN   (France)

^c UNIVERSITY OF ROUEN   (France)

^d faculté mixte de médecine et de pharmacie de Rouen   (France)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLCHOLINE; ENDOTHELIAL NITRIC OXIDE SYNTHASE; HYDROXYCHLOROQUINE; NITRIC OXIDE; PHOSPHOLIPID ANTIBODY; THROMBOPLASTIN; VASCULAR CELL ADHESION MOLECULE 1; NOS3 PROTEIN, HUMAN; NOS3 PROTEIN, MOUSE; THROMBIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIPHOSPHOLIPID SYNDROME; AORTIC ENDOTHELIAL CELL; ARTICLE; BLOOD CLOTTING; CARDIOVASCULAR FUNCTION; CAROTID ARTERY OBSTRUCTION; CELL FUNCTION; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENDOTHELIAL DYSFUNCTION; ENDOTHELIUM CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; INFLAMMATION; MALE; MESENTERIC ARTERY; MOUSE; NONHUMAN; PROTEIN EXPRESSION; PROTHROMBIN TIME; THROMBIN TIME; THROMBOSIS; VASCULAR ENDOTHELIAL CELL; ANIMAL; DISEASE MODEL; FEMALE; IMMUNOLOGY; PATHOLOGY; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIBODIES, ANTIPHOSPHOLIPID; ANTIPHOSPHOLIPID SYNDROME; DISEASE MODELS, ANIMAL; ENDOTHELIAL CELLS; ENDOTHELIUM, VASCULAR; FEMALE; HUMANS; HYDROXYCHLOROQUINE; MALE; MICE; NITRIC OXIDE SYNTHASE TYPE III; THROMBIN; THROMBOPLASTIN; THROMBOSIS; VASCULAR CELL ADHESION MOLECULE-1;

EID: 85062969655     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0212614     Document Type: Article

References (38)

1. Miyakis S, Lockshin MD, Atsumi T, Branch DW, Brey RL, Cervera R, et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost JTH. 2006; 4: 295-306. https://doi.org/10.1111/j.1538-7836.2006.01753.x PMID: 16420554
2. López-Pedrera C, Buendía P, Cuadrado MJ, Siendones E, Aguirre MA, Barbarroja N, et al. Antiphospholipid antibodies from patients with the antiphospholipid syndrome induce monocyte tissue factor expression through the simultaneous activation of NF-kappaB/Rel proteins via the p38 mitogen-acti-vated protein kinase pathway, and of the MEK-1/ERK pathway. Arthritis Rheum. 2006; 54: 301-311. https://doi.org/10.1002/art.21549 PMID: 16385547
3. Kinev AV, Roubey RAS. Tissue factor in the antiphospholipid syndrome. Lupus. 2008; 17: 952-958. https://doi.org/10.1177/0961203308096662 PMID: 18827061
4. Ahmed K, Vianna JL, Khamashta MA, Hughes GR. IL-2, IL-6 and TNF levels in primary antiphospholipid syndrome. Clin Exp Rheumatol. 1992; 10: 503. PMID: 1458705
5. Pierangeli SS, Espinola RG, Liu X, Harris EN. Thrombogenic effects of antiphospholipid antibodies are mediated by intercellular cell adhesion molecule-1, vascular cell adhesion molecule-1, and P-selectin. Circ Res. 2001; 88: 245-250. PMID: 11157679
6. Kaplanski G, Cacoub P, Farnarier C, Marin V, Grégoire R, Gatel A, et al. Increased soluble vascular cell adhesion molecule 1 concentrations in patients with primary or systemic lupus erythematosus-related antiphospholipid syndrome: correlations with the severity of thrombosis. Arthritis Rheum. 2000; 43: 55-64. https://doi.org/10.1002/1529-0131(200001)43:1<55::AID-ANR8>3.0.CO;2-M PMID: 10643700
7. Benhamou Y, Bellien J, Armengol G, Brakenhielm E, Adriouch S, Iacob M, et al. Role of toll-like receptors 2 and 4 in mediating endothelial dysfunction and arterial remodeling in primary arterial antiphospholipid syndrome. Arthritis Rheumatol. 2014;
8. Charakida M, Besler C, Batuca JR, Sangle S, Marques S, Sousa M, et al. Vascular abnormalities, para-oxonase activity, and dysfunctional HDL in primary antiphospholipid syndrome. JAMA J Am Med Assoc. 2009; 302: 1210-1217.
9. Mercanoglu F, Erdogan D, Oflaz H, Kücükkaya R, Selcukbiricik F, Gül A, et al. Impaired brachial endothelial function in patients with primary anti-phospholipid syndrome. Int J Clin Pract. 2004; 58: 1003-1007. PMID: 15605661
10. Tanne D, Katzav A, Beilin O, Grigoriadis NC, Blank M, Pick CG, et al. Interaction of inflammation, thrombosis, aspirin and enoxaparin in CNS experimental antiphospholipid syndrome. Neurobiol Dis. 2008; 30: 56-64. https://doi.org/10.1016/j.nbd.2007.12.004 PMID: 18308578
11. Benhamou Y, Miranda S, Armengol G, Harouki N, Drouot L, Zahr N, et al. Infliximab improves endothelial dysfunction in a mouse model of antiphospholipid syndrome: role of reduced oxidative stress. Vascul Pharmacol. 2015; 71: 93-101. https://doi.org/10.1016/j.vph.2015.03.014 PMID: 25869505
12. Schmidt-Tanguy A, Voswinkel J, Henrion D, Subra JF, Loufrani L, Rohmer V, et al. Antithrombotic effects of hydroxychloroquine in primary antiphospholipid syndrome patients. J Thromb Haemost JTH. 2013; 11: 1927-1929. https://doi.org/10.1111/jth.12363 PMID: 23902281
13. Espinola RG, Pierangeli SS, Gharavi AE, Harris EN, Ghara AE. Hydroxychloroquine reverses platelet activation induced by human IgG antiphospholipid antibodies. Thromb Haemost. 2002; 87: 518-522. PMID: 11916085
14. Rand JH, Wu X-X, Quinn AS, Ashton AW, Chen PP, Hathcock JJ, et al. Hydroxychloroquine protects the annexin A5 anticoagulant shield from disruption by antiphospholipid antibodies: evidence for a novel effect for an old antimalarial drug. Blood. 2010; 115: 2292-2299. https://doi.org/10.1182/blood-2009-04-213520 PMID: 19965621
15. Schreiber K, Breen K, Parmar K, Rand JH, Wu X-X, Hunt BJ. The effect of hydroxychloroquine on haemostasis, complement, inflammation and angiogenesis in patients with antiphospholipid antibodies. Rheumatol Oxf Engl. 2018; 57: 120-124.
16. Billoir P, Miranda S, Damian L, Richard V, Benhamou Y, Duchez VLC. Development of a thrombin generation test in cultured endothelial cells: Evaluation of the prothrombotic effects of antiphospholipid antibodies. Thromb Res. 2018; 169: 87-92. https://doi.org/10.1016/j.thromres.2018.07.021 PMID: 30031291
17. Ramesh S, Morrell CN, Tarango C, Thomas GD, Yuhanna IS, Girardi G, et al. Antiphospholipid antibodies promote leukocyte-endothelial cell adhesion and thrombosis in mice by antagonizing eNOS via β2GPI and apoER2. J Clin Invest. 2011; 121: 120-131. https://doi.org/10.1172/JCI39828 PMID: 21123944
18. Reverter JC, Tàssies D, Font J, Monteagudo J, Escolar G, Ingelmo M, et al. Hypercoagulable state in patients with antiphospholipid syndrome is related to high induced tissue factor expression on monocytes and to low free protein s. Arterioscler Thromb Vasc Biol. 1996; 16: 1319-1326. PMID: 8911269
19. Cuadrado MJ, López-Pedrera C, Khamashta MA, Camps MT, Tinahones F, Torres A, et al. Thrombosis in primary antiphospholipid syndrome: a pivotal role for monocyte tissue factor expression. Arthritis Rheum. 1997; 40: 834-841. https://doi.org/10.1002/1529-0131(199705)40:5<834::AID-ART8>3.0. CO;2-# PMID: 9153543
20. Dobado-Berrios PM, López-Pedrera C, Velasco F, Aguirre MA, Torres A, Cuadrado MJ. Increased levels of tissue factor mRNA in mononuclear blood cells of patients with primary antiphospholipid syndrome. Thromb Haemost. 1999; 82: 1578-1582. PMID: 10613637
21. Kornberg A, Blank M, Kaufman S, Shoenfeld Y. Induction of tissue factor-like activity in monocytes by anti-cardiolipin antibodies. J Immunol Baltim Md 1950. 1994; 153: 1328-1332.
22. Amengual O, Atsumi T, Khamashta MA, Hughes GR. The role of the tissue factor pathway in the hyper-coagulable state in patients with the antiphospholipid syndrome. Thromb Haemost. 1998; 79: 276-281. PMID: 9493575
23. Reverter JC, Tàssies D, Font J, Khamashta MA, Ichikawa K, Cervera R, et al. Effects of human monoclonal anticardiolipin antibodies on platelet function and on tissue factor expression on monocytes. Arthritis Rheum. 1998; 41: 1420-1427. https://doi.org/10.1002/1529-0131(199808)41:8<1420::AIDART11>3.0.CO;2-U PMID: 9704640
24. Zhou H, Wolberg AS, Roubey RAS. Characterization of monocyte tissue factor activity induced by IgG antiphospholipid antibodies and inhibition by dilazep. Blood. 2004; 104: 2353-2358. https://doi.org/10.1182/blood-2004-01-0145 PMID: 15226179
25. Pierangeli SS, Colden-Stanfield M, Liu X, Barker JH, Anderson GL, Harris EN. Antiphospholipid antibodies from antiphospholipid syndrome patients activate endothelial cells in vitro and in vivo. Circulation. 1999; 99: 1997-2002. PMID: 10209004
26. Prinz N, Clemens N, Canisius A, Lackner KJ. Endosomal NADPH-oxidase is critical for induction of the tissue factor gene in monocytes and endothelial cells. Lessons from the antiphospholipid syndrome. Thromb Haemost. 2013; 109: 525-531. https://doi.org/10.1160/TH12-06-0421 PMID: 23328933
27. Hemker HC, Al Dieri R, De Smedt E, Béguin S. Thrombin generation, a function test of the haemostatic-thrombotic system. Thromb Haemost. 2006; 96: 553-561. PMID: 17080210
28. Van Veen JJ, Gatt A, Makris M. Thrombin generation testing in routine clinical practice: are we there yet? Br J Haematol. 2008; 142: 889-903. https://doi.org/10.1111/j.1365-2141.2008.07267.x PMID: 18564356
29. Dienava-Verdoold I, Boon-Spijker MG, de Groot PG, Brinkman HJM, Voorberg J, Mertens K, et al. Patient-derived monoclonal antibodies directed towards beta2 glycoprotein-1 display lupus anticoagulant activity. J Thromb Haemost JTH. 2011; 9: 738-747. https://doi.org/10.1111/j.1538-7836.2011.04212.x PMID: 21255251
30. Regnault V, Béguin S, Wahl D, de Maistre E, Coenraad Hemker H, Lecompte T. Thrombinography shows acquired resistance to activated protein C in patients with lupus anticoagulants. Thromb Haemost. 2003; 89: 208-212. PMID: 12574797
31. Efthymiou M, Lawrie AS, Mackie I, Arachchillage D, Lane PJ, Machin S, et al. Thrombin generation and factor X assays for the assessment of warfarin anticoagulation in thrombotic antiphospholipid syndrome. Thromb Res. 2015; 135: 1191-1197. https://doi.org/10.1016/j.thromres.2015.03.030 PMID: 25895847
32. Rikarni null, Dharma R, Tambunan KL, Isbagyo H, Dewi BE, Acang N, et al. Prothrombotic Effect of Anti-beta-2 Glycoprotein-1 Antibodies on the Expression of Tissue Factor, Thrombomodulin, and Plas-minogen Activator Inhibitor-1 in Endothelial Cells. Acta Medica Indones. 2015; 47: 31-37.
33. Edwards MH, Pierangeli S, Liu X, Barker JH, Anderson G, Harris EN. Hydroxychloroquine reverses thrombogenic properties of antiphospholipid antibodies in mice. Circulation. 1997; 96: 4380-4384. PMID: 9416907
34. Cohen H, Hunt BJ, Efthymiou M, Arachchillage DRJ, Mackie IJ, Clawson S, et al. Rivaroxaban versus warfarin to treat patients with thrombotic antiphospholipid syndrome, with or without systemic lupus erythematosus (RAPS): a randomised, controlled, open-label, phase 2/3, non-inferiority trial. Lancet Haematol. 2016; 3: e426-436. https://doi.org/10.1016/S2352-3026(16)30079-5 PMID: 27570089
35. Sacharidou A, Chambliss KL, Ulrich V, Salmon JE, Shen Y-M, Herz J, et al. Antiphospholipid antibodies induce thrombosis by PP2A activation via apoER2-Dab2-SHC1 complex formation in endothelium. Blood. 2018; 131: 2097-2110. https://doi.org/10.1182/blood-2017-11-814681 PMID: 29500169
36. Li R, Lin H, Ye Y, Xiao Y, Xu S, Wang J, et al. Attenuation of antimalarial agent hydroxychloroquine on TNF-α-induced endothelial inflammation. Int Immunopharmacol. 2018; 63: 261-269. https://doi.org/10.1016/j.intimp.2018.08.008 PMID: 30121047
37. Müller-Calleja N, Manukyan D, Canisius A, Strand D, Lackner KJ. Hydroxychloroquine inhibits proin-flammatory signalling pathways by targeting endosomal NADPH oxidase. Ann Rheum Dis. 2017; 76: 891-897. https://doi.org/10.1136/annrheumdis-2016-210012 PMID: 27903507
38. Müller-Calleja N, Hollerbach A, Häuser F, Canisius A, Orning C, Lackner KJ. Antiphospholipid antibody-induced cellular responses depend on epitope specificity: implications for treatment of antiphospholipid syndrome. J Thromb Haemost. 15: 2367-2376. https://doi.org/10.1111/jth.13865 PMID: 29024318